arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

TREACE MEDICAL CONCEPTS, INC.

TMCI

$4.77 ▲ +0.36 (+8.29%) at close

8 Visible periods

30 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

TREACE MEDICAL CONCEPTS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $301.8M

Dividend Yield —

Revenue Growth 1.6% ↘

Op. Margin -25.5% ↗

ROIC -29.9% ↘

FCF / Share $-0.47 ↗

Trailing P/E —

Price / Book 3.5x

FCF Yield —

Debt / Equity 0.66

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$212.69M

↑ +1.6% —

Net Income Profit after all expenses

$-59.00M

↓ -5.8% —

Operating Margin Operating profit as % of sales

-25.5%

↑ +4.3% 9th

FCF / Share Free cash flow per share

$-0.47

↑ +40.6% —

Long-Term Debt Long-term obligations

$55.58M

↑ +4.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓

Returns ↓

Financial Health →

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	1.6% Caution ↓ Caution Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-80%)	11.9% Good ↓ Good Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+49%)	31.9% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+299%)	50.2% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+528%)	64.6% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+707%)	45.5% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+469%)	—	—
EPS Growth YoY (%)	-3.3% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-11.1% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-5.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-79.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-5.8% Weak ↑ Weak Improving Year-over-year change in net income	-12.6% Weak ↑ Weak Improving Year-over-year change in net income	-15.7% Weak ↑ Weak Improving Year-over-year change in net income	-108.3% Weak ↑ Weak Improving Year-over-year change in net income	-460.3% Weak Weak Year-over-year change in net income	14.0% Fair Fair Year-over-year change in net income	—	—
FCF Growth YoY (%)	40.6% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-3.8% Weak ↑ Weak Improving Year-over-year change in free cash flow	8.1% Fair Fair Year-over-year change in free cash flow	-100.2% Weak Weak Year-over-year change in free cash flow	—	—	—	—
Revenue CAGR 3Y (%)	14.5% Good ↓ Good Declining Compound annual revenue growth over 3 years	30.4% Excellent ↓ Excellent Declining Compound annual revenue growth over 3 years	48.3% Excellent Excellent Compound annual revenue growth over 3 years	53.2% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	30.0% Excellent Excellent Compound annual revenue growth over 5 years	39.7% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Operating Margin (%) (%)	-25.5% Weak → Weak Stable Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-270%)	-26.6% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-277%)	-27.5% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-283%)	-24.6% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-264%)	-17.5% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-217%)	1.5% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-90%)	-9.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-160%)	—
Profit Margin (%) (%)	-27.7% Weak → Weak Stable Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-331%)	-26.6% Weak → Weak Stable Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-322%)	-26.5% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-321%)	-30.2% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-352%)	-21.8% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-281%)	-6.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-153%)	-10.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-190%)	—
FCF Margin (%) (%)	-13.9% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-23.3% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-24.6% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-32.1% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-21.1% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-9.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-22.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.50x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.06x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.52x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	2.08x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-29.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-26.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-21.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-24.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-10.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	2.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-88.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-28.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-25.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-20.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-21.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-11.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	2.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-67.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-550%)	-49.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-429%)	-35.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-339%)	-70.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-572%)	-22.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-247%)	—	-134.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1000%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Debt to Equity (x)	0.66x Fair ↑ Fair Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+9%)	0.47x Good ↓ Good Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-21%)	0.38x Good ↓ Good Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-36%)	0.87x Fair ↓ Fair Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+45%)	0.32x Good Good Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-47%)	39.92x Weak Weak Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+6553%)	—	—
Interest Coverage (x)	-10.18x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-10.60x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-9.95x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-7.92x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-4.07x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	0.31x Weak Weak Operating income divided by interest expense Optimal: > 5x	-4.20x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$46.62M	$41.96M	$40.03M	$33.24M	$-76.47M	$12.90M	$-12.14M	$-1.28M
Debt / EBITDA (x)	-1.32x Excellent → Excellent Stable Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.13x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.15x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.61x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.86x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	15.00x Weak Weak Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$3.36	$3.37	$3.07	$2.57	$1.95	—	—	—
Basic EPS, GAAP (USD)	$-0.93	$-0.90	$-0.81	$-0.77	$-0.43	—	—	—
Free Cash Flow per Share (USD)	$-0.47	$-0.79	$-0.76	$-0.82	$-0.41	—	—	—
Book Value per Share (USD)	$1.38	$1.82	$2.23	$1.09	$1.72	—	—	—
Tangible Book Value per Share (USD)	$1.07	$1.48	$1.88	$1.09	$1.72	—	—	—
Basic Weighted Avg Shares (shares)	63.27M	62.11M	60.85M	55.28M	48.42M	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$101.42M	$126.48M	$153.33M	$103.16M	$119.76M	$29.38M	—	—
LT Debt (USD)	$55.58M	$53.31M	$53.01M	$52.71M	$29.36M	$30.98M	—	—
Total Equity (USD)	$87.33M	$112.89M	$137.94M	$60.53M	$93.07M	$776.00K	$3.16M	$5.95M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$212.69M	$209.36M	$187.12M	$141.84M	$94.42M	$57.37M	$39.42M	—
Depreciation Expense (USD)	$10.62M	$8.42M	$5.35M	$2.13M	$685.00K	$1.21M	$793.00K	—
Net Income, GAAP (USD)	$-59.00M	$-55.74M	$-49.53M	$-42.81M	$-20.55M	$-3.67M	$-4.26M	—
Operating Cash Flow (USD)	$-15.97M	$-37.17M	$-34.58M	$-30.65M	$-17.19M	$-4.49M	$-7.67M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 27 quarters

TREACE MEDICAL CONCEPTS, INC.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare TMCI with peers